A Src-like inactive conformation in the Abl tyrosine kinase domain

PLoS Biology

Volumn 4, Issue 5, 2006, Pages 753-767

  Levinson, Nicholas M ^a   Kuchment, Olga ^a   Shen, Kui ^b   Young, Matthew A ^a,e   Koldobskiy, Michael ^b   Karplus, Martin ^c   Cole, Philip A ^b   Kuriyan, John ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HARVARD UNIVERSITY   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; ABELSON KINASE; ASPARTIC ACID; BCR ABL PROTEIN; GLYCINE; IMATINIB; MACROGOL 3350; PHENYLALANINE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; COMPLEX FORMATION; CONJUGATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG INHIBITION; DRUG PROTEIN BINDING; ENZYME CONFORMATION; ENZYME STRUCTURE; MOLECULAR DYNAMICS; MUTATION; NONHUMAN; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIMULATION; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CHRONIC MYELOID LEUKEMIA; DRUG RESISTANCE; ENZYME ACTIVATION; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN TERTIARY STRUCTURE;

AMINO ACID MOTIFS; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, MOLECULAR; PIPERAZINES; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SRC-FAMILY KINASES;

EID: 33646755174     PISSN: 15457885     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.0040144     Document Type: Article

References (72)

1. Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109: 275-282.
2. Kannan N, Neuwald AF (2005) Did protein kinase regulatory mechanisms evolve through elaboration of a simple structural component? J Mol Biol 351: 956-972.
3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561-566.
4. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, et al. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289: 1938-1942.
5. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, et al. (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure 6: 1117-1128.
6. Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5: 33-44.
7. Xu W, Doshi A, Lei M, Eck MJ, Harrison SC (1999) Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell 3: 629-638.
8. Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, et al. (1999) Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol Cell 3: 639-648.
9. Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, et al. (2003) Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112: 859-871.
10. Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, et al. (2003) A myristoyl/phosphotyrosine switch regulates c-Abl. Cell 112: 845-857.
11. Hubbard SR (1997) Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J 16: 5572-5581.
12. Hubbard SR, Wei L, Ellis L, Hendrickson WA (1994) Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372: 746-754.
13. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, et al. (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279: 31655-31663.
14. Griffith J, Black J, Faerman C, Swenson L, Wynn M, et al. (2004) The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13: 169-178.
15. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, et al. (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855-867.
16. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9: 268-272.
17. Lamers MB, Antson AA, Hubbard RE, Scott RK, Williams DH (1999) Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 285: 713-725.
18. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, et al. (2003) A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348: 1201-1214.
19. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, et al. (2002) Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 347: 481-487.
20. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
21. De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, et al. (1993) Crystal structure of cyclin-dependent kinase 2. Nature 363: 595-602.
22. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64: 6652-6659.
23. Padyana AK, Qiu H, Roll-Mecak A, Hinnebusch AG, Burley SK (2005) Structural basis for autoinhibition and mutational activation of eukaryotic initiation factor 2alpha protein kinase GCN2. J Biol Chem 280: 29289-29299.
24. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS (2002) Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol 9: 117-120.
25. Parang K, Cole PA (2002) Designing bisubstrate analog inhibitors for protein kinases. Pharmacol Ther 93: 145-157.
26. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, et al. (2004) VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 10: 262-267.
27. Young MA, Shah NP, Chao LH, Seeliger M, Milanov ZV, et al. (2006) Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res 66: 1007-1014.
28. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, et al. (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62: 4236-4243.
29. Wisniewski D, Lambek CL, Liu C, Strife A, Veach DR, et al. (2002) Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res 62: 4244-4255.
30. Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, et al. (2001) Mechanism-based design of a protein kinase inhibitor. Nat Struct Biol 8: 37-41.
31. Wilmot CM, Thornton JM (1988) Analysis and prediction of the different types of beta-turn in proteins. J Mol Biol 203: 221-232.
32. Chekmarev DS, Ishida T, Levy RM (2004) Long-time conformational transitions of alanine dipeptide in aqueous solution: Continuous and discrete-state kinetic models. J Phys Chem B 108: 19487-19495.
33. Karplus M, Kuriyan J (2005) Molecular dynamics and protein function. Proc Natl Acad Sci U S A 102: 6679-6685.
34. Schlitter J, Engels M, Kruger P (1994) Targeted molecular dynamics: A new approach for searching pathways of conformational transitions. J Mol Graph 12: 84-89.
35. Isralewitz B, Gao M, Schulten K (2001) Steered molecular dynamics and mechanical functions of proteins. Curr Opin Struct Biol 11: 224-230.
36. Torrie GM, Valleau JP (1977) Non-physical sampling distributions in Monte-Carlo free-energy estimation: Umbrella sampling. J Comput Phys 23: 187-199.
37. Neria E, Fischer S, Karplus M (1996) Simulation of activation free energies in molecular systems. J Chem Phys 105: 1902-1921.
38. Tobias DJ, Brooks CL (1987) Calculation of free-energy surfaces using the methods of thermodynamic perturbation-theory. Chem Phys Lett 142: 472-476.
39. Rees DC, Lewis M, Lipscomb WN (1983) Refined crystal structure of carboxypeptidase A at 1.54 A resolution. J Mol Biol 168: 367-387.
40. Yamaguchi H, Hendrickson WA (1996) Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384: 484-489.
41. Burley SK, Petsko GA (1986) Amino-aromatic interactions in proteins. FEBS Lett 203: 139-143.
42. Watson JD, Milner-White EJ (2002) A novel main-chain anion-binding site in proteins: The nest: A particular combination of phi, psi values in successive residues gives rise to anion-binding sites that occur commonly and are found often at functionally important regions. J Mol Biol 315: 171-182.
43. Karlsson R, Zheng J, Xuong N, Taylor SS, Sowadski JM (1993) Structure of the mammalian catalytic subunit of cAMP-dependent protein kinase and an inhibitor peptide displays an open conformation. Acta Crystallogr D Biol Crystallogr 49: 381-388.
44. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385: 602-609.
45. Xu W, Harrison SC, Eck MJ (1997) Three-dimensional structure of the tyrosine kinase c-Src. Nature 385: 595-602.
46. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876-880.
47. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117-125.
48. Azam M, Latek RR, Daley GQ (2003) Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
49. Al-Ali HK, Heinrich MC, Lange T, Krahl R, Mueller M, et al. (2004) High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. Hematol J 5: 55-60.
50. Gonfloni S, Weijland A, Kretzschmar J, Superti-Furga G (2000) Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat Struct Biol 7: 281-286.
51. Miething C, Mugler C, Grundler R, Hoepfl J, Bai RY, et al. (2003) Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo. Leukemia 17: 1695-1699.
52. O'Hare T, Druker BJ (2005) BIRB-796 is not an effective ABL(T315I) inhibitor. Nat Biotechnol 23: 1209-1210.
53. Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, et al. (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23: 329-336.
54. Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW (2003) Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101: 4611-4614.
55. Sullivan JE, Holdgate GA, Campbell D, Timms D, Gerhardt S, et al. (2005) Prevention of MKK6-dependent activation by binding to p38alpha MAP kinase. Biochemistry 44: 16475-16490.
56. Vogtherr M, Saxena K, Hoelder S, Grimme S, Betz M, et al. (2005) NMR characterization of kinase p38 dynamics in free and ligand-bound forms. Angew Chem Int Ed Engl 45: 993-997.
57. Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, et al. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 14: 3135-3139.
58. Songyang Z, Carraway KL III, Eck MJ, Harrison SC, Feldman RA, et al. (1995) Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature 373: 536-539.
59. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Macromol Crystallogr A 276: 307-326.
60. McCoy AJ, Grosse-Kunstleve RW, Storoni LC, Read RJ (2005) Likelihood-enhanced fast translation functions. Acta Crystallogr D Biol Crystallogr 61: 458-464.
61. Brunger AT, Adams PD, Clore GM, DeLano WL, Gros P, et al. (1998) Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 54: 905-921.
62. Kleywegt GJ, Jones TA (1996) Efficient rebuilding of protein structures. Acta Crystallogr D Biol Crystallogr 52: 829-832.
63. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
64. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, et al. (1995) A 2nd generation force-field for the simulation of proteins, nucleic-acids, and organic-molecules. J Am Chem Soc 117: 5179-5197.
65. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, et al. (1995) Amber, a package of computer-programs for applying molecular mechanics, normal-mode analysis, molecular-dynamics and free-energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun 91: 1-41.
66. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, et al. (1996) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules (Addition/correction for 117: 5179). J Am Chem Soc 118: 2309.
67. Ryckaert JP, Ciccotti G, Berendsen HJC (1977) Numerical-integration of Cartesian equations of motion of a system with constraints: Molecular-dynamics of N-alkanes. J Comput Phys 23: 327-341.
68. Darden T, York D, Pedersen L (1993) Particle mesh Ewald: An N.Log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089-10092.
69. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J (2001) Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 105: 115-126.
70. Case DA, Pearlman DA, Caldwell JW, Cheatham TEI, Wang J, et al. (2002) AMBER 7 [computer program]. San Francisco: University of California, San Francisco.
71. Brooks BR, Bruccoleri RE, Olafson BD, States DJ, Swaminathan S, et al. (1983) Charmm: A program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4: 187-217.
72. DeLano WL (2002) The PyMOL molecular graphics system [computer program]. San Carlos (California): DeLano Scientific.